At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 33 enrolled
Drug / intervention
instillation of NOV03drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of NOV03 on the Tear Film in Subjects With Dry Eye Disease
In Brief
A Phase 4 clinical trial evaluating instillation of NOV03 for Dry Eye Disease (DED). Completed, enrolled 33 participants across 1 site.
Detailed Summary
Determine the effect of a single instillation of NOV03 on the thickness and evaporation rate of the mucus-aqueous layer of the tear film
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Disease (DED)
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
202420252026
First PostedFeb 2023
Enrollment StartAug 2023
Primary CompletionDec 2023
TodayJul 2026
First PostedFeb 13, 2023
Enrollment StartAug 14, 2023
Primary CompletionDec 23, 2023
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 3.4 years ago
Interventions
instillation of NOV03drug
This trial consists of 2 office visits over a period of approximately 2 weeks. At Visit 2, a designated clinical staff member or the investigator will instill 1 drop of NOV03 into each eye.